^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Aromatase inhibitor

    Related drugs:
    5d
    SIE-3: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Rovi Pharmaceuticals Laboratories | Trial completion date: Jun 2031 --> Dec 2033 | Initiation date: May 2026 --> Aug 2026
    Trial completion date • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    8d
    BabyTEARS: Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, Dana-Farber Cancer Institute
    New P2 trial
    |
    ER (Estrogen receptor) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2) • IGF1 (Insulin-like growth factor 1)
    |
    tamoxifen • exemestane
    11d
    Myo-Inositol for Infertility in PCOS (clinicaltrials.gov)
    P=N/A, N=168, Recruiting, University of Oklahoma | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    letrozole
    13d
    A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women. (2023-503948-13-00)
    P1, N=105, Completed, Laboratorios Farmaceuticos Rovi S.A. | Active, not recruiting --> Completed
    Trial completion
    |
    letrozole
    14d
    Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (clinicaltrials.gov)
    P3, N=132, Recruiting, Ente Ospedaliero Ospedali Galliera | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AR (Androgen receptor)
    |
    carboplatin • paclitaxel • letrozole
    27d
    Protective Effects of Hesperidin on Letrozole-Induced Neurotoxicity: Involvement of Oxidative Stress, Apoptotic Signaling, and Inflammation. (PubMed, J Biochem Mol Toxicol)
    These findings indicate that hesperidin confers neuroprotection by restoring redox balance, regulating apoptosis, and suppressing inflammation in letrozole-induced neurotoxicity. Further studies are warranted to elucidate the precise molecular mechanisms and potential therapeutic applications of hesperidin in letrozole-induced neurotoxicity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    HR positive
    |
    letrozole
    27d
    Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report. (PubMed, Front Oncol)
    At last follow-up (OS: 108 months), she maintained SD with minimal toxicity. This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
    Journal
    |
    ER (Estrogen receptor)
    |
    HR positive
    |
    letrozole • megestrol
    1m
    Comparison of frozen embryo transfer outcomes in hormonal vs. mild stimulation protocols in polycystic ovary syndrome women: A randomized controlled trial. (PubMed, Int J Reprod Biomed)
    In HRT, oral estradiol followed by injectable progesterone was used; in MOS, letrozole +  follicle-stimulating hormone stimulation continued until follicle    17 mm and endometrium     7.5 mm, then human chorionic gonadotropin was given. However, the number of clinical pregnancies (p = 0.045) and the number of successful pregnancies (p = 0.049) were significantly higher in the MOS group compared to the HRT group. This study showed that MOS achieved higher clinical and successful pregnancy rates than HRT in women with PCOS.
    Journal
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • LIFR (LIF Receptor Subunit Alpha) • LIF (LIF Interleukin 6 Family Cytokine)
    |
    letrozole
    1m
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    1m
    BabyTears: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. (clinicaltrials.gov)
    P2, N=95, Recruiting, Andrea DeCensi | N=70 --> 95
    Enrollment change
    |
    ER (Estrogen receptor) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    tamoxifen • exemestane
    1m
    FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov)
    P3, N=462, Completed, AstraZeneca | Trial completion date: Aug 2027 --> Jan 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    fulvestrant • anastrozole
    1m
    FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, University of Novi Sad
    New trial
    |
    letrozole